Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MOLN

Molecular Partners AG ADR

Nov 06 • 02:37PM ET

4.50

+0.47 11.77 %

Healthcare • Biotechnology • Switzerland • NASD

Peers: BPMC FATE SRPT NBIX IONS ALNY RARE ARWR INCY EXEL

Index	-	P/E	-	EPS (ttm)	-1.91	Insider Own	0.28%	Shs Outstand	37.40M	Perf Week	19.36%
Market Cap	168.30M	Forward P/E	-	EPS next Y	-1.79	Insider Trans	0.00%	Shs Float	37.30M	Perf Month	21.29%
Enterprise Value	38.86M	PEG	-	EPS next Q	-0.39	Inst Own	9.59%	Short Float	0.08%	Perf Quarter	13.92%
Income	-70.94M	P/S	-	EPS this Y	-2.47%	Inst Trans	0.11%	Short Ratio	5.63	Perf Half Y	16.01%
Sales	0.00M	P/B	1.40	EPS next Y	7.83%	ROA	-43.82%	Short Interest	0.03M	Perf YTD	-5.22%
Book/sh	3.21	P/C	1.28	EPS next 5Y	7.78%	ROE	-49.86%	52W High	6.24 -27.88%	Perf Year	-6.06%
Cash/sh	3.51	P/FCF	-	EPS past 3/5Y	7.12% -1.12%	ROIC	-58.90%	52W Low	3.36 33.93%	Perf 3Y	-39.19%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-19.13% -22.75%	Gross Margin	-	Volatility	9.51% 4.64%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	11.02%	Oper. Margin	-	ATR (14)	0.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.28	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	68.49	Recom	1.57
Dividend Gr. 3/5Y	- -	Current Ratio	9.28	EPS Q/Q	30.66%	SMA20	17.84%	Beta	1.07	Target Price	10.03
Payout	-	Debt/Eq	0.02	Sales Q/Q	-100.00%	SMA50	19.68%	Rel Volume	0.77	Prev Close	4.03
Employees	174	LT Debt/Eq	0.00	Earnings	Oct 30 AMC	SMA200	9.64%	Avg Volume	5.16K	Price	4.50
IPO	Jun 16, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	3,216	Change	11.77%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-30-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-29-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$30 → $8
May-25-22	Upgrade	Credit Suisse	Underperform → Neutral
Apr-27-22	Downgrade	Credit Suisse	Neutral → Underperform
Jul-13-21	Initiated	Cowen	Outperform	$50
Jul-12-21	Resumed	SVB Leerink	Outperform	$36

Nov-03-25 01:00AM	Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting (GlobeNewswire) +12.42%
01:00AM	Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025 (GlobeNewswire)
Oct-30-25 04:00PM	Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025 (GlobeNewswire)
Aug-25-25 04:00PM	Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025 (GlobeNewswire) +14.85% -7.71%
Aug-21-25 01:00AM	Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics (GlobeNewswire)
04:00PM	Loading…
Jun-22-25 04:00PM	Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 (GlobeNewswire)
Jun-11-25 04:00PM	Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025 (GlobeNewswire) +8.03%
Jun-10-25 01:00AM	Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway (GlobeNewswire)
May-19-25 01:00AM	Molecular Partners to Present at Upcoming Investor Conferences (GlobeNewswire)
May-15-25 04:00PM	Molecular Partners Reports Financial Results and Highlights from Q1 2025 (GlobeNewswire)
Apr-25-25 04:00PM	Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025 (GlobeNewswire)
Apr-16-25 12:00PM	Molecular Partners Announces all Board Proposals Approved at Annual General Meeting (GlobeNewswire) -8.70%
Apr-03-25 09:55AM	Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher (Zacks)
Mar-25-25 04:00PM	Molecular Partners to hold three poster presentations at AACR 2025 (GlobeNewswire) +10.70%
12:00PM	Molecular Partners Publishes Invitation to Annual General Meeting 2025 (GlobeNewswire)
04:00PM	Loading…
Mar-06-25 04:00PM	Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024 (GlobeNewswire)
Feb-28-25 01:00AM	Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call (GlobeNewswire)
Jan-12-25 01:00PM	Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
01:00PM	Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer (GlobeNewswire)
Dec-17-24 04:00PM	Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January (GlobeNewswire)
Dec-08-24 12:00PM	Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024 (GlobeNewswire)
Nov-07-24 04:00PM	Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024 (GlobeNewswire)
Nov-05-24 04:00PM	Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition (GlobeNewswire) -5.06% +8.52%
Oct-31-24 04:00PM	Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going (GlobeNewswire) -12.85% +14.18%
Oct-25-24 01:00AM	Molecular Partners Announces Pricing of $20 Million Underwritten Offering (GlobeNewswire) +7.81%
Oct-23-24 09:29AM	Molecular Partners Expands Radio-DARPin Collaboration (TipRanks) -13.71%
Oct-22-24 01:00AM	Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics (GlobeNewswire)
01:00AM	Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024 (GlobeNewswire)
Oct-04-24 01:00AM	Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting (GlobeNewswire) +9.61%
Sep-27-24 01:00AM	Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024 (GlobeNewswire) +8.10%
04:00PM	Loading…
Aug-26-24 04:00PM	Molecular Partners Reports H1 2024 Corporate Highlights and Financials (GlobeNewswire) +11.79%
Jul-14-24 12:16PM	30 Wealthiest People in Switzerland (Insider Monkey)
Jun-24-24 07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -25.10%
Jun-20-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) +38.32%
Jun-17-24 01:00AM	Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit (GlobeNewswire) +7.68%
Jun-14-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +13.78%
01:00AM	Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024 (GlobeNewswire)
Jun-12-24 07:46AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) +16.23%
Jun-11-24 01:00AM	Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024 (GlobeNewswire) +13.41%
Jun-01-24 08:00AM	Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024 (GlobeNewswire)
May-16-24 04:00PM	Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program (GlobeNewswire)
Apr-29-24 11:00AM	Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action (GlobeNewswire)
Apr-19-24 11:12AM	Life Science Cares Launches in Switzerland (GlobeNewswire) -11.23%
Apr-17-24 11:12AM	Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting (GlobeNewswire)
Mar-26-24 09:26AM	Molecular Partners Publishes Invitation to Annual General Meeting 2024 (GlobeNewswire)
Mar-14-24 04:00PM	Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023 (GlobeNewswire)
Mar-01-24 04:00PM	Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations (GlobeNewswire)
Jan-07-24 04:00PM	Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-24 04:00PM	Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies (GlobeNewswire) +11.79%
Dec-14-23 01:00AM	Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences (GlobeNewswire) +7.41%
Dec-10-23 12:00PM	Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting (GlobeNewswire)
Nov-14-23 01:00AM	Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS) (GlobeNewswire)
Nov-03-23 12:00PM	Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting (GlobeNewswire) +10.53%
Nov-02-23 02:00AM	Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition (GlobeNewswire) +14.52%
Nov-01-23 02:00AM	Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit (GlobeNewswire)
Oct-26-23 04:00PM	Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio (GlobeNewswire) +5.32%
Sep-13-23 01:00AM	Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting (GlobeNewswire) -5.41%
Aug-24-23 04:00PM	Molecular Partners Reports H1 2023 Corporate Highlights and Financials (GlobeNewswire)
Jul-13-23 08:06AM	Owning 32% shares,hedge funds owners seem interested in Molecular Partners AG (VTX:MOLN), (Simply Wall St.)
Jun-27-23 01:00AM	Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023 (GlobeNewswire)
Jun-19-23 12:00PM	Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit (GlobeNewswire)
Jun-02-23 08:59AM	Companies Like Molecular Partners (VTX:MOLN) Are In A Position To Invest In Growth (Simply Wall St.)
May-25-23 05:01PM	Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting (GlobeNewswire)
May-16-23 04:00PM	Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference (GlobeNewswire) -5.55%
May-13-23 02:00AM	Getting In Cheap On Molecular Partners AG (VTX:MOLN) Is Unlikely (Simply Wall St.)
May-11-23 04:00PM	Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy (GlobeNewswire) +5.75%
Apr-18-23 01:44AM	Investors in Molecular Partners (VTX:MOLN) have unfortunately lost 79% over the last five years (Simply Wall St.) -7.09%
Apr-14-23 01:00AM	Molecular Partners to Present Additional Preclinical Data Supporting the Companys Radio DARPin Therapy Platform at AACR (GlobeNewswire)
Apr-04-23 11:44AM	Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting (GlobeNewswire)
Mar-13-23 09:30AM	Molecular Partners Publishes Invitation to Annual General Meeting 2023 (GlobeNewswire) +9.04%
12:22AM	Molecular Partners AG (NASDAQ:MOLN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-11-23 02:14AM	Molecular Partners Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Mar-09-23 04:00PM	Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022 (GlobeNewswire) -5.31%
Mar-02-23 04:00PM	Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care Conference (GlobeNewswire)
Feb-28-23 01:15AM	Molecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy Platform (GlobeNewswire)
Feb-10-23 01:00AM	Molecular Partners to Present at SVB Leerink Global Healthcare Conference (GlobeNewswire)
Jan-16-23 01:00AM	Molecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid Leukemia (GlobeNewswire)
Jan-12-23 06:18AM	Hedge funds own 28% of Molecular Partners AG (VTX:MOLN) shares but individual investors control 41% of the company (Simply Wall St.)
Jan-08-23 03:00PM	Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference (GlobeNewswire)
Dec-30-22 01:00AM	Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor Conferences (GlobeNewswire) +6.16%
Dec-12-22 07:00PM	Molecular Partners Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML (GlobeNewswire)
Dec-01-22 11:46PM	Molecular Partners AG's (VTX:MOLN) Stock's On An Uptrend: Are Strong Financials Guiding The Market? (Simply Wall St.) +10.62%
Nov-10-22 01:00AM	Molecular Partners Presents Positive Interim Safety and Mechanistic Data From Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors (GlobeNewswire)
Nov-04-22 09:39AM	Investors in Molecular Partners (VTX:MOLN) have unfortunately lost 77% over the last five years (Simply Wall St.)
Nov-03-22 12:30PM	Molecular Partners Announces Acceptance of Oral Presentation at the Annual American Society of Hematology Meeting (GlobeNewswire)
Nov-02-22 12:30PM	Molecular Partners Announces Upcoming Participation in Investor and Scientific Conferences (GlobeNewswire)
Oct-27-22 04:00PM	Molecular Partners Announces Planned Departure of Chief Financial Officer (GlobeNewswire)
04:00PM	Interim Management Statement Q3 2022: Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End (GlobeNewswire)
Aug-25-22 04:30PM	Molecular Partners Reports Corporate Highlights and H1 2022 Financials (GlobeNewswire) +10.16% -7.35%
Aug-18-22 01:00AM	Molecular Partners Half Year 2022 News Release and Investor Call Details (GlobeNewswire)
Jul-21-22 11:30AM	Molecular Partners Announces Publication in Nature Biotechnology Detailing Design and Mechanism of Ensovibep DARPin Antiviral for SARS-CoV-2 (GlobeNewswire)
Jun-10-22 01:00AM	Molecular Partners Announces Participation in Scientific Conferences (GlobeNewswire)
May-12-22 04:05PM	Interim Management Statement Q1 2022 of Molecular Partners: Cash Runway into 2026 and Portfolio Progress Highlight Strategic Momentum (GlobeNewswire) +13.55%
May-11-22 01:00AM	Molecular Partners to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire)
May-03-22 12:00PM	Molecular Partners CEO, Patrick Amstutz, Elected President of the Swiss Biotech Association (GlobeNewswire)
Apr-27-22 08:02AM	Molecular Partners shares tumble 37% after Amgen returns rights to tumor treatment candidate (MarketWatch) -37.37%
06:01AM	Molecular Partners Regains Rights To Early-Stage Cancer Asset From Amgen (Benzinga)
05:59AM	Molecular Partners, Novartis Note EUA For COVID-19 Therapy May Need Additional Data (Benzinga)
Apr-26-22 04:05PM	Molecular Partners to Regain Global Rights for MP0310 from Amgen (GlobeNewswire) -16.17%
02:00PM	Molecular Partners Provides Update on Ensovibep Following Novartis Quarterly Earnings Call (GlobeNewswire)

Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274, and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Pluckthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MOLN

Molecular Partners AG ADR

Upgrade your FINVIZ experience